MedTrace Logo

Spironolactone Plus Metformin in Polycystic Ovary Syndrome

NCT01526616 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2012-02-06

No results posted yet for this study

Summary

The investigators examined whether a combined therapy with low-dose spironolactone plus metformin is more effective than metformin alone in 52 overweight/obese Polycystic Ovary Syndrome (PCOS) patients.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Metformin

Metformin 850 mg twice a day for six months

DRUG

Metformin plus Spironolactone

Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day

Sponsors & Collaborators

  • University Magna Graecia

    lead OTHER

Principal Investigators

  • A. Mazza B. Fruci A. Belfiore, Doctors · Endocrinology Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-05-31
Completion
2011-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01526616 on ClinicalTrials.gov